Prolonging the life of people with metastatic breast cancer in routine clinical practice by adding palbociclib to an aromatase inhibitor from a real-world database analysis: a plain language summary.

Hope S Rugo,Adam Brufsky,Xianchen Liu,Benjamin Li,Lynn McRoy,Connie Chen,Rachel M Layman,Massimo Cristofanilli,Mylin A Torres,Giuseppe Curigliano,Richard S Finn,Angela DeMichele

Future oncology (London, England)（2023）

引用 0|浏览36

暂无评分

摘要

These results support the continued use of palbociclib plus an AI as the standard first medicine to be given to people with metastatic HR+/HER2- breast cancer. : NCT05361655 (ClinicalTrials.gov).

查看译文

关键词

HR+/HER2–,aromatase inhibitor,lay summary,metastatic breast cancer,overall survival,palbociclib,plain language summary,real-world

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要